Smart Pump Patents: Who Leads, Where the Gaps Are 2026
- 93.2% concentration. The top 5 of 18 ranked assignees hold 69 of the 74 records in scope — this field is not a level playing field for a new entrant.
- Filing has cooled since the 2019 peak. 19 filings that year against 2 so far in the partial 2026 count, with a documented -60% swing from 2021 (5) to 2024 (2).
- Healthcare informatics dominates the claim map. G16H appears on 70.3% of the 74 records, well ahead of the physical device class A61M at 45.9%.
Filing growth compares 2021 (5 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 74 records in scope (CR5), not by the ranked leaders only.
What the smart pump patent record shows
Smart infusion pumps and dose error reduction software sit at the intersection of two claim traditions: the physical delivery device (A61M) and the software layer that governs drug libraries, hard limits and alert logic (G16H, G06F). In this 74-record set, the informatics side carries more of the claim weight than the device side, which tells a filer that the contested ground has moved from pump mechanics to the rules engines and data formats that sit on top of them.
Filing concentrated hard in 2019 and has not returned to that level since, though the two most recent years in any such trend are always undercounted because publication lags filing by roughly 18 months. Read the 2021-to-2024 decline as the reliable comparison point, not the partial years after it.
Filing trend and technology composition
The underlying counts behind the charts: annual filing volume by publication year, and the IPC subclasses that recur across the 74 records in scope.
Filing trend, 2017-2026
Filings ran from 6 in 2017 to a peak of 19 in 2019, then declined; 2021 (5) to 2024 (2) is a documented -60% move over the most recent complete three-year span. 2025 and 2026 figures will rise as later publications catch up.
IPC subclass composition
G16H (healthcare informatics) touches 70.3% of the 74 records, A61M (body-fluid devices) 45.9%, and G06F (digital data processing) 23.0%. Because records can carry multiple classes, these shares sum past 100% and should not be read as mutually exclusive segments.
Shares are the percentage of the 74 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Smart Pumps and Dose Error Reduction with Eureka
This page is one run against one query. Ask Eureka your own question about smart pumps and dose error reduction and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
Drug library compiler for patient devices (US20210233638A1)
A compiler system and method for providing a drug library to patient devices includes a memory and a processing circuit. The memory stores a drug library in a first format, comprising drug data used by software on patient devices to program administration according to a protocol set at least in part by a user. The processing circuit identifies the patient device type from prestored types, selects a compiler program from prestored options, and translates the drug library from the first format into a selected second format for storage and use on the device.Filed by Fresenius Vial SAS, published 2021-07-29.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20060258985A1 | Graphical display of medication limits and delivery program | 304 |
| 2 | US20160051750A1 | Medication infusion safety device and a medication infusion device comprising the medication infusion safety … | 87 |
| 3 | US20170262590A1 | Default data set distribution for medical devices | 67 |
| 4 | WO2019219290A1 | Drug library compiler for patient devices | 64 |
| 5 | US20190006044A1 | System and method of synchronizing medical device databases | 58 |
| 6 | US10740436B2 | Data set distribution during medical device operation | 47 |
| 7 | EP2987517A1 | Medication infusion safety device with reservoir recognition and connection verification | 30 |
| 8 | US20170147761A1 | Data set distribution during medical device operation | 29 |
| 9 | US20160361492A1 | Medical Device with Automated Modality Switching | 17 |
| 10 | WO2006124202A1 | Graphical display of medication limits and delivery program | 10 |
Citation counts reward older records that have had more time to accumulate citations inside the searched corpus — treat them as a signal of influence on the field, not a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the ranking, the trend and the IPC composition are read together.
Claim space is held by very few hands
Five assignees account for 69 of the 74 records in scope, and the ranked list of 18 companies covers all of it by the tenth position. A new entrant is not filing into open ground; it is filing adjacent to a small number of established drug-library and hard-limit portfolios.
The 2019 peak has not been repeated
Filing rose to 19 records in 2019 and has since fallen, with the 2021-to-2024 window showing a -60% move from 5 to 2 filings. Because publication lags filing by roughly 18 months, the 2025-2026 figures should not yet be read as confirming or breaking that decline.
Informatics claims outweigh device claims
G16H healthcare informatics appears on more records than the physical delivery class A61M, and G06F digital data processing sits behind both. The contested claim territory has shifted toward drug library formats, alert logic and interoperability rather than pump hardware alone.
Older filings still anchor the field
The most-cited record in this set, on graphical display of medication limits, dates well back in the window and carries far more citations than recent filings can yet accumulate. New work should treat that citation gap as an artefact of time in the corpus, not as proof the newer filings matter less.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to smart pumps and dose error reduction, with the prior art for and against each one.
Who holds the ground and where it is still open
The ranked leaders sit atop a long tail of single- or double-filing entrants, several of them individual named inventors rather than corporate assignees.
One filer holds close to a third of the set
The top-ranked assignee's 23 records, against a field of 74, sets the scale for everyone below it; fifth place holds 5 and tenth place holds just 1, a steep drop that marks this as a leader-and-long-tail structure rather than a broad field of comparable competitors.
The tail is thin but present
All 74 records in scope are accounted for by just 18 ranked assignees, several appearing to be individual inventors rather than device manufacturers. That mix suggests some filings originate outside the established infusion-device manufacturer base.
Collaboration is limited and clustered
Only 10 co-assignee pairs appear across the set, and the strongest recurring pairings involve the same small group of individual filers appearing together on multiple records rather than cross-company joint ventures.
| Assignee | Recent year | YoY |
|---|---|---|
| UMAMAHESWARI D | 1 | — |
| SRUTHI DHARANI KARANAM SAI | 1 | — |
| SPARSHA K O | 1 | — |
| SHAH PRIYANKA | 1 | — |
| Fresenius Vial | 0 | — |
| Fenwal Inc | 0 | — |
| CareFusion 303 Inc | 0 | -100% |
| MICREL MEDICAL DEVICES SA | 0 | — |
Where to take this from here
The dataset points to specific next steps rather than a single conclusion.
Map claims against the top 5 concentration
Before drafting in the drug-library or hard-limit space, check freedom-to-operate against the assignees holding 93.2% of the 74 records — that concentration is the single biggest constraint on a new filing strategy.
Explore assignee claims in EurekaWatch the 2025-2026 publication catch-up
The apparent decline after 2019 is real through 2024 but the last two years are still filling in; re-check the trend once later publications land before treating it as a settled slowdown.
Track filing trends in EurekaProbe the under-claimed branches
Interoperability formats and alert-fatigue logic show thinner filing density than the core device and drug-library claims — a first-mover claim there faces less prior art to design around.
Run a white space search in EurekaCommon questions about smart pump and dose error reduction patents
Highly concentrated. In this 74-record set, the top five of 18 ranked assignees hold 69 records between them, or 93.2% of everything in scope, and the top ten cover all 74 records. That means a new filer is almost certainly building claims adjacent to a small number of established portfolios rather than entering open territory, so a freedom-to-operate check against the leading assignees is a sensible first step before drafting.
Filing peaked in 2019 at 19 records and declined over the following years; the documented comparison from 2021 (5 records) to 2024 (2 records) shows a -60% change over that three-year span. Because publication typically lags filing by around 18 months, the 2025 and 2026 counts in any dataset are still incomplete, so it is too early to call this a permanent slowdown rather than a reporting gap that will partially fill in.
Healthcare informatics, IPC class G16H, appears on 70.3% of the 74 records in this set, ahead of the physical delivery device class A61M at 45.9% and general data processing class G06F at 23.0%. That ordering indicates the more contested claim territory now sits in drug library formats, alert logic and interoperability rather than pump hardware design alone, which matters for where R&D and IP budget should be weighted.
US20210233638A1, filed by Fresenius Vial SAS and published 2021-07-29, claims a compiler system that translates a drug library from one format into a second format selected for a specific patient device type, using a memory storing the drug library and a processing circuit that identifies device type and selects a matching compiler program. It is aimed at the interoperability problem of getting one drug library to run correctly across different infusion device models. Anyone building cross-device drug library translation or format-conversion tooling should read this claim set closely before designing a similar pipeline.
The IPC composition shows thin coverage in classes adjacent to the dominant G16H and A61M clusters: data recognition and presentation (G06K, 5.4% of records), diagnosis-linked dosing (A61B, 2.7%), and transmission protocols (H04L, 2.7%). These lower-density branches, alongside cross-device interoperability formats and alert-fatigue suppression logic, are areas where fewer of the 74 records stake a claim, making them more open for a first-mover filing than the core drug-library space.
Research Smart Pumps and Dose Error Reduction in depth with Eureka
Go past this page: query the whole smart pumps and dose error reduction corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.